Detection of antibodies to infliximab in routine care: a 4-year French retrospective study.

IF 3.4 3区医学 Q3 IMMUNOLOGY Clinical and experimental immunology Pub Date : 2025-01-21 DOI:10.1093/cei/uxae122

Daniel Bertin, Jehanne Aghzadi, Nathalie Balandraud, Céline Roman, Mélanie Serrero, Sophie Desplat-Jégo

{"title":"Detection of antibodies to infliximab in routine care: a 4-year French retrospective study.","authors":"Daniel Bertin, Jehanne Aghzadi, Nathalie Balandraud, Céline Roman, Mélanie Serrero, Sophie Desplat-Jégo","doi":"10.1093/cei/uxae122","DOIUrl":null,"url":null,"abstract":"<p><p>Despite its wide use to treat various inflammatory diseases, infliximab becomes ineffective in some patients due to inadequate drug levels and production of anti-drug antibodies (ADA). The aim of this study was to compare the prevalence and ADA levels in a large cohort of patients. ADA and infliximab (IFX) through levels measured by enzyme-linked immunosorbent assay were collected from 505 patients within a period of 4 years. The results indicate that (i) 13.5% of patients produce ADA, (ii) male patients were more likely to produce ADA at levels above 10 000 ng/ml than female patients, (iii) ADA levels were lower when associated with immunosuppressant drugs, (iv) there was an inverse relationship between ADA presence and IFX detection, and (v) no correlation was observed between ADA levels and number of injections or brand of IFX administered. This study improves our understanding of the factors promoting IFX immunogenicity and highlights the need to develop personalized treatment strategies.</p>","PeriodicalId":10268,"journal":{"name":"Clinical and experimental immunology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747995/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cei/uxae122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Despite its wide use to treat various inflammatory diseases, infliximab becomes ineffective in some patients due to inadequate drug levels and production of anti-drug antibodies (ADA). The aim of this study was to compare the prevalence and ADA levels in a large cohort of patients. ADA and infliximab (IFX) through levels measured by enzyme-linked immunosorbent assay were collected from 505 patients within a period of 4 years. The results indicate that (i) 13.5% of patients produce ADA, (ii) male patients were more likely to produce ADA at levels above 10 000 ng/ml than female patients, (iii) ADA levels were lower when associated with immunosuppressant drugs, (iv) there was an inverse relationship between ADA presence and IFX detection, and (v) no correlation was observed between ADA levels and number of injections or brand of IFX administered. This study improves our understanding of the factors promoting IFX immunogenicity and highlights the need to develop personalized treatment strategies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

常规护理中英夫利昔单抗抗体的检测：一项为期4年的法国回顾性研究。

尽管英夫利昔单抗广泛用于治疗各种炎症性疾病，但由于药物水平不足和抗药物抗体（ADA）的产生，英夫利昔单抗在一些患者中变得无效。本研究的目的是比较大量患者的患病率和ADA水平，通过ELISA测量的ADA和IFX水平收集了505名患者在四年的时间内。结果表明：1)13.5%的患者产生ADA， 2)男性患者在水平高于10000 ng/mL时比女性患者更容易产生ADA， 3)与免疫抑制药物相关时ADA水平较低，4)ADA存在与IFX检测呈反比关系，5)ADA水平与注射次数或使用的IFX品牌之间无相关性。这项研究提高了我们对促进IFX免疫原性的因素的理解，并强调了制定个性化治疗策略的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and experimental immunology 医学-免疫学

CiteScore

8.40

自引率

2.20%

发文量

101

审稿时长

3-8 weeks

期刊介绍： Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.